Home / Poster / Application of PBPK modelling for prediction of tacrolimus exposure in CYP3A combined genotype groups (CYP3A4*22 and/or CYP3A5*3) and a renal transplant population

Poster

Application of PBPK modelling for prediction of tacrolimus exposure in CYP3A combined genotype groups (CYP3A422 and/or CYP3A53) and a renal transplant population

Application of PBPK modelling for prediction of tacrolimus exposure in CYP3A combined genotype groups (CYP3A422 and/or CYP3A53) and a renal transplant population

Recommended for you

How Model-informed drug development rescue projects from a risky situation

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

On-Demand Webinar

Certara’s Simcyp Educational Webinar Series: Learn from A to Z of PBBM Part 2: What is the Drug Absorption Model?

© 2025 Certara. All Rights Reserved. | Privacy policy